NIH R01 · 2025
Targeted vaccines against pulmonary NTM infections in vulnerable populations
NTM infections have now surpassed tuberculosis in the U.S. and are a global concern. Long (>12 months) treatment regimens and severe toxic side effects of drug treatment warrant urgent development of new strategies. We hypothesize that a vaccine targeted against pathogenic NTM will improve immunity in at- risk individuals, prevent NTM-lung disease (NTM-LD), and improve therapeutic clinical outcomes when used as an adjunct to drug treatment. We propose the development of two innovative NTM-LD vaccine candidates: an adjuvated subunit vaccine and a novel replicon RNA-based vaccine. The 13 vaccine candidate antigens, which have known importance in Mycobacterium avium (MAV) and Mycobacteroides…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.